1. Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial  News-Medical.Net
  2. SARS-CoV-2 spike E484K mutation reduces antibody neutralisation  The Lancet
  3. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351 - nejm.org  nejm.org
  4. The interaction between blood clotting and SARS-CoV-2 infection  News-Medical.Net
  5. Bispecific antibodies neutralize SARS-CoV-2 and its variants  News-Medical.Net
  6. View Full coverage on Google News
A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.A new preprint research paper posted to the medRxiv server reports the results of the first human trial of the prefusion stabilized SARS-CoV-2 spike vaccine MVC-COV1901 in Taiwan.

Prefusion SARS-CoV-2 spike-based vaccine candidate shows high safety and efficacy in phase I trial

DEFINE_ME

www.nejm.org